Quotient Ltd
Healthcare · In Vitro & In Vivo Diagnostic Substances · Y9 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $38.5M | $43.4M | $32.7M | $29.1M | $24.7M | $22.2M |
| Operating income | −$103.8M | −$82.5M | −$80.7M | −$79.0M | −$70.0M | −$74.1M |
| Net income | −$125.1M | −$108.5M | −$102.8M | −$105.4M | −$82.3M | −$85.1M |
| Total assets | $194.0M | $219.3M | $226.5M | $177.8M | $123.8M | $110.0M |
| Total liabilities | $338.1M | $248.3M | $232.0M | $176.1M | $138.5M | $134.1M |
| Equity | −$144.1M | −$29.0M | −$5.5M | $1.7M | −$14.6M | −$24.1M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 103.2M | 101.5M | 80.6M | 66.2M | 45.8M | 37.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −269.6%
- Net margin
- −324.9%
- Return on equity
- 86.8%
- Return on assets
- −64.5%
- Return on capital (ROCE)
- −64.4%
- Liabilities / assets
- 174.3%
- Debt / equity
- —
- Book value / share
- $-1.40
- Revenue growth (YoY)
- −11.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -13.90distress
- Accruals / assets
- −3.1%clean
- Beneish M-Score
- -2.13normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 16, 2021
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Modified shareholder rights · Director / officer changeJun 14, 2023
- Modified shareholder rights · Shareholder voteApr 27, 2023
- Entered a material agreement · Bankruptcy or receivership · Director / officer changeFeb 22, 2023
- Entered a material agreement · Bankruptcy or receivership · Debt acceleration / triggering eventJan 10, 2023
- Entered a material agreementJan 9, 2023
- Entered a material agreement · Delisting / listing-standard noticeDec 19, 2022
- Delisting / listing-standard noticeDec 12, 2022
- Entered a material agreement · Costs from exit or disposalDec 8, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15-12GJun 30, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- EFFECTJun 29, 2023
- POS AMFORM POS AMJun 26, 2023
- POS AMFORM POS AMJun 26, 2023
- POS AMFORM POS AMJun 26, 2023
- POS AMFORM POS AMJun 26, 2023
- POS AMFORM POS AMJun 26, 2023
- POS AMFORM POS AMJun 26, 2023